Disrupting glioblastoma networks with tumor treating fields (TTFields) in in vitro models

被引:1
|
作者
Schlieper-Scherf, Steffen [1 ]
Hebach, Nils [2 ,3 ,4 ]
Hausmann, David [2 ,3 ,4 ]
Azorin, Daniel D. [2 ,3 ,4 ]
Hoffmann, Dirk C. [2 ,3 ,4 ]
Horschitz, Sandra [5 ,6 ]
Maier, Elena [1 ]
Koch, Phillip [5 ,6 ]
Karreman, Matthia A. [2 ,3 ,4 ]
Etminan, Nima [1 ]
Ratliff, Miriam [1 ,2 ]
机构
[1] Heidelberg Univ, Univ Hosp Mannheim, Dept Neurosurg, Mannheim, Germany
[2] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Clin Cooperat Unit Neurooncol, Heidelberg, Germany
[3] Univ Hosp Heidelberg, Neurol Clin, Heidelberg, Germany
[4] Univ Hosp Heidelberg, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] Heidelberg Univ, Cent Inst Mental Hlth, Med Fac Mannheim, Mannheim, Germany
[6] Hector Inst Translat Brain Res HITBR gGmbH, Mannheim, Germany
关键词
Glioma; Cancer neuroscience; Tumor microtubes; Cancer cell network; TTFields; ELECTRIC-FIELD; CELLS; RADIOTHERAPY; CANCER;
D O I
10.1007/s11060-024-04786-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeThis study investigates the biological effect of Tumor Treating Fields (TTFields) on key drivers of glioblastoma's malignancy-tumor microtube (TM) formation-and on the function and overall integrity of the tumor cell network.MethodUsing a two-dimensional monoculture GB cell network model (2DTM) of primary glioblastoma cell (GBC) cultures (S24, BG5 or T269), we evaluated the effects of TTFields on cell density, interconnectivity and structural integrity of the tumor network. We also analyzed calcium (Ca2+) transient dynamics and network morphology, validating findings in patient-derived tumoroids and brain tumor organoids.ResultsIn the 2DTM assay, TTFields reduced cell density by 85-88% and disrupted network interconnectivity, particularly in cells with multiple TMs. A "crooked TM" phenotype emerged in 5-6% of treated cells, rarely seen in controls. Ca2+ transients were significantly compromised, with global Ca2+ activity reduced by 51-83%, active and periodic cells by over 50%, and intercellular co-activity by 52% in S24, and almost completely in BG5 GBCs. The effects were more pronounced at 200 kHz compared to a 50 kHz TTFields. Similar reductions in Ca2+ activity were observed in patient-derived tumoroids. In brain tumor organoids, TTFields significantly reduced tumor cell proliferation and infiltration.ConclusionOur comprehensive study provides new insights into the multiple effects of Inovitro-modeled TTFields on glioma progression, morphology and network dynamics in vitro. Future in vivo studies to verify our in vitro findings may provide the basis for a deeper understanding and optimization of TTFields as a therapeutic modality in the treatment of GB.
引用
收藏
页码:139 / 151
页数:13
相关论文
共 50 条
  • [41] INCREASED CANCER CELL PERMEABILITY FOLLOWING TUMOR TREATING FIELDS (TTFIELDS) APPLICATION IN VITRO
    Voloshin, Tali
    Porat, Yaara
    Kaynan, Noa
    Klein-Goldberg, Anat
    Paz, Rom
    Volodin, Alexandra
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    NEURO-ONCOLOGY, 2020, 22 : 102 - 102
  • [42] Tumor treating fields (TTFields) in combination with sorafenib inhibit hepatocellular carcinoma in vitro and in vivo
    Potter, Wyatt
    Davidi, Shiri
    Jacobovitch, Sara
    Shteingauz, Anna
    Tempel-Brami, Catherine
    Zeevi, Einav
    Dor-On, Eyal
    Schneiderman, Rosa S.
    Voloshin, Tali
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Kinzel, Adrian
    Weinberg, Uri
    Palti, Yoram
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [43] DEVELOPMENT OF TUMOR TREATING FIELDS (TTFIELDS) ARRAYS FOR TREATMENT OF HEAD TUMORS IN MICE MODELS
    Zbidat, Sewar
    Blat, Roni
    Sellevoll, Mariell
    Gabay, Martin
    Schlachet, Inbar
    Cahal, Shay
    Davidi, Shiri
    Tzchori, Itai
    Haber, Adi
    Giladi, Moshe
    Palti, Yoram
    NEURO-ONCOLOGY, 2023, 25
  • [44] IN VITRO TUMOR TREATING FIELDS (TTFIELDS) APPLIED PRIOR TO RADIATION ENHANCES THE RESPONSE TO RADIATION IN PATIENT-DERIVED GLIOBLASTOMA CELL LINES
    Michelhaugh, Sharon
    Mittal, Sandeep
    NEURO-ONCOLOGY, 2019, 21 : 89 - 89
  • [45] Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy
    Ramirez, Andres Felipe Guerrero
    Tang, Cynthia Crystal
    Kong, Xiao-Tang
    Bota, Daniela Annenelie
    Chang, Peter D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] B IN VIVO EFFICACY OF TUMOR TREATING FIELDS (TTFIELDS) FOR GLIOBLASTOMA USING NOVEL MOUSE HEAD ARRAYS
    Zbidat, S.
    Blatt, R.
    Sellevoll, M.
    Gabay, M.
    Schlachet, I
    Cahal, S.
    Davidi, S.
    Tzchori, I
    Haber, A.
    Giladi, M.
    Palti, Y.
    NEURO-ONCOLOGY, 2024, 26
  • [47] Compatibility of topical agents with tumor treating fields (TTFields) for treatment of associated skin events in glioblastoma (GBM).
    Giladi, Moshe
    Lacouture, Mario E.
    Weinberg, Uri
    Bomzon, Zeev
    Palti, Yoram
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma
    Dono, Antonio
    Mitra, Sonali
    Shah, Mauli
    Takayasu, Takeshi
    Zhu, Jay-Jiguang
    Tandon, Nitin
    Patel, Chirag B.
    Esquenazi, Yoshua
    Ballester, Leomar Y.
    JOURNAL OF NEURO-ONCOLOGY, 2021, 153 (01) : 153 - 160
  • [49] Designing arrays for the mouse head to facilitate in vivo studies of Tumor Treating Fields (TTFields) treatment of glioblastoma
    Zbidat, Sewar
    Blatt, Roni
    Sellevoll, Mariell
    Gabay, Martin
    Schlachet, Inbar
    Cahal, Shay
    Davidi, Shiri
    Tzchori, Itai
    El-Mabhouh, Amal
    Haber, Adi
    Giladi, Moshe
    Palti, Yoram
    CANCER RESEARCH, 2024, 84 (05)
  • [50] Tumor Treating Fields (TTFields) may be utilized to increase temozolomide and lomustine efficacy in glioblastoma cell lines
    Fishman, Hila
    Monin, Roni
    Dor-On, Eyal
    Haber, Adi
    Gastl, Bastian
    Giladi, Moshe
    Weinberg, Uri
    Palti, Yoram
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 148 - 148